Barrett's oesophagus
Disease1 paper2 findings
- Humans1
Upstream
2GIPR
no changein silico1OR 1
1 study
GIPR
no changein silico1OR 1
GIPR has no effect on Barrett's oesophagus in silico (OR 1.00, 95% CI 0.42-2.37).
“estimates were near the null for both receptors (GLP-1R 0.96, 0.47-1.96; GIPR 1.00, 0.42-2.37)”
In silico
Genetic Assessment of Oesophageal Safety of GLP-1 and GIP Receptor Perturbation: A Drug-Target Mendelian Randomisation Study · Biomedicines · 24 Aug 2026
GLP1R
no changein silico1OR 0.96
1 study
GLP1R
no changein silico1OR 0.96
GLP1R has no effect on Barrett's oesophagus in silico (OR 0.96, 95% CI 0.47-1.96).
“For the Barrett's oesophagus/adenocarcinoma endpoint, estimates were near the null for both receptors (GLP-1R 0.96, 0.47-1.96; GIPR 1.00, 0.42-2.37)”
In silico
Genetic Assessment of Oesophageal Safety of GLP-1 and GIP Receptor Perturbation: A Drug-Target Mendelian Randomisation Study · Biomedicines · 24 Aug 2026